Fresenius Kabi (Acquired Dabur Pharma) in South Africa

Fresenius Kabi’s Strategic Expansion in South Africa’s Healthcare Sector

Johannesburg, August 2, 2025 – Fresenius Kabi, a global leader in infusion therapy and clinical nutrition, has been actively enhancing its presence in South Africa’s healthcare market through strategic acquisitions and partnerships.

Acquisition of Dabur Pharma

In April 2008, Fresenius Kabi expanded its oncology portfolio by acquiring a 73.3% stake in Dabur Pharma Ltd., a leading manufacturer of oncology generics based in New Delhi, India. The acquisition was completed in August 2008, with Dabur Pharma subsequently rebranded as Fresenius Kabi Oncology. (fresenius.com, business-standard.com)

Entry into South African Market

Fresenius Kabi’s initial foray into the South African market occurred in 2004, when it established a presence through the acquisition of local companies. (fresenius-kabi.com) This move aimed to strengthen its position in the region and expand its product offerings.

Recent Developments

In February 2024, the South African Competition Tribunal approved, subject to conditions, the merger between Life Healthcare Group (Pty) Ltd and the dialysis services business of Fresenius Medical Care South Africa (Pty) Ltd. This merger is expected to enhance the delivery of dialysis services across the country. (comptrib.kerrykazadi.com)

Conclusion

Fresenius Kabi’s strategic acquisitions and partnerships underscore its commitment to expanding its footprint in South Africa’s healthcare sector, aiming to provide high-quality medical products and services to meet the evolving needs of the South African population.